Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 3 , Pages 277-283 , May 2009

Livin may serve as a marker for prognosis of bladder cancer relapse and a target of bladder cancer treatment

  • Hai-Bo Liu, M.D.

      Affiliations

    • Department of Urology, The First Hospital of China Medical University, Shenyang, China
    • ,
  • Chui-Ze Kong, M.D.

      Affiliations

    • Department of Urology, The First Hospital of China Medical University, Shenyang, China
    • Corresponding Author InformationCorresponding author. Tel.: +86-24-83283433; fax: +86-24-83283433
    • ,
  • Yu Zeng, M.D.

      Affiliations

    • Department of Urology, The First Hospital of China Medical University, Shenyang, China
    • Department of Urology, Kagawa University Faculty of Medicine, Kagawa, Japan
    • ,
  • Xian-Kui Liu, M.D.

      Affiliations

    • Department of Urology, The First Hospital of China Medical University, Shenyang, China
    • ,
  • Jian-Bin Bi, M.D.

      Affiliations

    • Department of Urology, The First Hospital of China Medical University, Shenyang, China
    • ,
  • Yuan-Jun Jiang, M.D.

      Affiliations

    • Department of Urology, The First Hospital of China Medical University, Shenyang, China
    • ,
  • Sheng Han, M.D.

      Affiliations

    • Department of Neurosurgery, The First Hospital of China Medical University, Shenyang, China

Received 28 December 2007 ,Revised 10 March 2008 ,Accepted 10 March 2008.

References 

  1. Jaattela M. Escaping cell death: Survival proteins in cancer. Exp Cell Res. 1999;248:30–43
  2. Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol. 1999;11:68–75
  3. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456–1462
  4. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol. 1999;17:2941–2953
  5. LaCasse EC, Baird S, Korneluk RG, et al. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 1998;17:3247–3259
  6. Deveraux QL, Roy N, Stennicke HR, et al. IAPs block apoptotic events induced by caspase 8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998;17:2215–2223
  7. Hengartner MO. Genetic control of programmed cell death and aging in the nematode Caenorhabditis elegans. Exp Gerontol. 1997;32:363–374
  8. Cohen GM. Caspases: The executioners of apoptosis. Biochem J. 1997;326:1–16
  9. Thornberry NA. The caspase family of cysteine proteases. Br Med Bull. 1997;53:478–490
  10. Hengartner MO. Death cycle and Swiss army knives. Nature. 1998;391:441–442
  11. Crook NE, Clem RJ, Miller LK. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol. 1993;67:2168–2174
  12. Rothe M, Pan MG, Henzel WJ, et al. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell. 1995;83:1243–1252
  13. Duckett CS, Nava VE, Gedrich RW, et al. A conserved family of cellular genes related to the baculovirus IAP gene and encoding apoptosis inhibitors. EMBO J. 1996;15:2685–2694
  14. Liston P, Roy N, Tamai K, et al. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature. 1996;379:349–353
  15. Ambrosini G, Adida C, Altieri DC. A novel antiapoptosis gene, Survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917–921
  16. Salvesen GS, Duckett CS. IAP proteins: Blocking the road to death's door. Nat Rev Mol Cell Biol. 2002;3:401–410
  17. Roy N, Deveraux QL, Takahashi R, et al. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 997;16:6914–25.
  18. Chu ZL, McKinsey TA, Liu L, et al. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-κB control. Proc Natl Acad Sci USA. 1997;94:10057–10062
  19. You M, Ku PT, Hrdlickova R, et al. ch-IAP1, a member of the inhibitor-of-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein. Mol Cell Biol. 1997;17:7328–7341
  20. Takahashi R, Deveraux Q, Tamm I, et al. A single BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem. 1998;273:7787–7790
  21. Clem RJ, Miller LK. Control of programmed cell death by the baculovirus genes p35 and IAP. Mol Cell Biol. 1994;14:5212–5222
  22. Lin JH, Deng G, Huang Q, et al. KIAP, a novel member of the inhibitor of apoptosis protein family. Biochem Biophys Res Commun. 2000;279:820–831
  23. Kasof GM, Gomes BC. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem. 2001;276:3238–3246
  24. Vucic D, Stennicke HR, Pisabarro MT, et al. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol. 2000;10:1359–1366
  25. Ashhab Y, Alian A, Polliack A, et al. Two splicing variants of anew inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett. 2001;495:56–60
  26. Yagihashi A, Asanuma K, Tsuji N, et al. Detection of anti-Livin antibody in gastrointestinal cancer patients. Clin Chem. 2003;49:1206–1208
  27. Gazzaniga P, Gradilone A, Giuliani L, et al. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol. 2003;14:85–90
  28. Kim DK, Alvarado CS, Abramowsky CR, et al. Expression of inhibitor-of-apoptosis protein (IAP) Livin by neuroblastoma cells: Correlation with prognostic factors and outcome. Pediatr Dev Pathol. 2005;8:621–629
  29. Eller MS, Ostrom K, Gilchrest BA. DNA damage enhances melanogenesis. Proc Natl Acad Sci USA. 1996;93:1087–1092
  30. Loo DT, Rillema JR. Measurement of cell death. Methods Cell Biol. 1998;57:251–264
  31. Youn BS, Kim YJ, Mantel C, et al. Blocking of c-FLIP(L) independent cycloheximide-induced apoptosis or Fas-mediated apoptosis by the CC chemokine receptor 9/TECK interaction. Blood. 2001;98:925–933
  32. Jinquan T, Jacobi HH, Jing C, et al. CCR3 expression induced by IL-2 and IL-4 functioning as a death receptor for B cells. J Immunol. 2003;171:1722–1731
  33. Ansell SM, Arendt BK, Grote DM, et al. Inhibition of Survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia. 2004;18:616–623
  34. Pennati M, Binda M, Colella G, et al. Ribozyme-mediated inhibition of Survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene. 2004;23:386–394
  35. Liu T, Brouha B, Grossman D. Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene. 2004;23:39–48
  36. Andersen MH, Reker S, Becker JC, et al. The melanoma inhibitor of apoptosis protein: A target for spontaneous cytotoxic T cell responses. J Invest Dermatol. 2004;122:392–399
  37. Bortner CD, Cidlowski JA. Cellular mechanisms for the repression of apoptosis. Annu Rev Pharmacol Toxicol. 2002;42:259–281
  38. Rothe M, Pan MG, Henzel WJ, et al. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell. 1995;83:1243–1252
  39. Deveraux QL, Reed JC. IAP family proteins—suppressors of apoptosis. Genes Dev. 1999;13:239–252
  40. Vucic D, Deshayes K, Ackerly H, et al. SMAC negatively regulates the antiapoptotic activity of melanoma inhibitor of apoptosis (MLIAP). J Biol Chem. 2002;277:12275–12279
  41. Vucic D, Franklin MC, Wallweber HJ, et al. Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: Implications for SMAC-dependent antiapoptotic activity of ML-IAP. Biochem J. 2005;385:11–20
  42. Zhang QP, Xiong J, Jin Y-X, et al. CC chemokine ligand 25 enhances resistance to apoptosis in CD4+ T cells from patients with T-cell lineage acute and chronic lymphocytic leukemia by means of Livin activation. Cancer Res. 2004;64:7579–7587
  43. Nachmias B, Ashhab Y, Bucholtz V, et al. Caspase-mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: Implications for drug-resistant melanoma. Cancer Res. 2003;63:6340–6349
  44. Hariu H, Hirohashi Y, Torigoe T, et al. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer. Clin Cancer Res. 2005;11:1000–1009
  45. Hara I, Miyake H, Takechi Y, et al. Clinical outcome of conservative therapy for stage T1, grade3 transitional cell carcinoma of the bladder. Int J Urol. 2003;10:19–24

PII: S1078-1439(08)00064-1

doi: 10.1016/j.urolonc.2008.03.015

Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 3 , Pages 277-283 , May 2009

Article Tools

* Image Usage & Resolution